A study by Mayo Clinic researchers published in Kidney International Reports found that point-of-care inhibitors, in some patients, may include adverse effects including inflammatory kidney inflammation, known as interstitial nephritis. Immune point protectors are used to treat cancer by stimulating the immune system to attack cancer cells.
Immune point-of-view protectors have improved the prognosis for patients with a wide range of malignancies including melanoma, non-small cell lung cancer and kidney cancer. In some patients, this enhanced immune response may target renal failure, leading to chronic renal inflammation known as interstitial nephritis. “
Sandra Herrmann, MD, Mayo Clinic Nephrologist and Lead Author of the Study
Dr. Herrmann says that a kidney biopsy is the gold standard for diagnosing this condition. However, renal biopsy is an invasive procedure that some patients may not be able to proceed because of the risk of bleeding.
“Our study provides important, first-time data for clinicians and patients about the use of biomarkers to routinely assess the cause of major renal injury in patients receiving point-of-care immunosuppressive therapy. for cancer, “says Dr. Herrmann.” These biomarkers could help doctors discriminate kidney damage related to other causes and could help reduce joint pain. clinical decisions related to whether check-back protection should continue if the detected injury is not related to immunotherapy. “
For this study, researchers followed patients seen at the Mayo Clinic for severe renal injury from 2014 to 2020. They found blood signals of renal activity and inflammation, serum creatinine and C-reactive protein, half, in addition to urine symptoms – urine protein-to-urine protein-to-urine ratio retinol – were significantly higher in patients with severe renal injury due to interstitial nephritis associated with immune checkpoint inhibitor therapy compared with other patients treated with immunotherapy but with severe renal injury due to other causes, such as acute tubular necrosis associated with other cancer treatments.
“Being able to tell if severe kidney injury in cancer patients is the result of a particular type of cancer treatment without the need for an aggressive test is very important,” says Dr Herrmann. “It simplifies the process for patients , making the procedure safer and faster, and helping physicians to better guide patients through their care. “
Dr. Herrmann says it is possible for patients to continue with cancer immunotherapy, which can be life-saving. In addition, she says patients with severe renal failure have a profound prognostic effect and need to be treated properly, so it’s important to quickly identify the cause.
Source:
Magazine Reference:
Isik, B., et al. (2021) Biomarkers, Clinical Features, and Recycling for Immunosuppression Event Immune Deprivation-Related Adverse Events. Kidney International Reports. doi.org/10.1016/j.ekir.2021.01.013.